

Reference number(s)
2759-H

SPECIALTY QUANTITY LIMIT PROGRAM

COPIKTRA (duvelisib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Copiktra (duvelisib) 15 mg capsules	56 per 28 days	Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) OR Follicular lymphoma (FL): 25 mg twice daily Dose modification for toxicity or drug interactions: 15 mg twice daily
Copiktra (duvelisib) 25 mg capsules	56 per 28 days	

III. REFERENCES

1. Copiktra [package insert]. Needham, MA: Verastem, Inc.; September 2018.